{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:56Z","timestamp":1781643536443,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monitoring of unfractionated heparin (UFH) in critically ill patients is challenging due to disease-related alterations of the coagulation system, directly affecting conventional laboratory tests, including activated partial thromboplastin time (aPTT). Measurement of anti-factor Xa activity (Anti-Xa) as an alternative to aPTT often lacks 24\/7 availability. Whole blood viscoelastic testing (VET) may provide a feasible point-of-care alternative to guide UFH dosing in this setting. Additionally, VET is readily available in the environment found in our clinic, The aim of this study was to evaluate the diagnostic performance of viscoelastic testing compared with activated partial thromboplastin time for monitoring unfractionated heparin in critically ill patients and to define clinically applicable viscoelastic thresholds using anti-factor Xa activity as the reference standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective observational study for UFH monitoring Anti-Xa, aPTT, and the VET clotting time IN\/HI ratio (ClotPro\u00ae; Haemonetics, Boston, MA, USA) were determined in simultaneously taken blood samples. Anti-Xa results were used as the reference standard to categorize ongoing UFH anticoagulation intensity into four categories (prophylactic, sub-therapeutic, therapeutic, and overdosed). Diagnostic performance of aPTT and CT IN\/HI ratio were evaluated against Anti-Xa using ROC analysis and Cohen\u2019s Kappa. Test performance was evaluated using ROC analysis, multiclass classification, and weighted Cohen\u2019s kappa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between September 2020 and July 2022, 466 datasets from 75 ICU patients receiving intravenous UFH were analyzed. Compared to aPTT, AUC values for CT IN\/HI were higher for detecting prophylactic (0.817 vs. 0.726), therapeutic (0.690 vs. 0.494) and overdosed (0.845 vs. 0.708) UFH levels. Thresholds of\u2009&gt;\u20091.4,\u2009&gt;\u20091.9, and\u2009&gt;\u20092.3 for the CT IN\/HI ratio corresponded to sub-therapeutic, therapeutic, and overdosed ranges, respectively. The CT IN\/HI ratio showed moderate agreement with Anti-Xa classification (\u03ba\u2009=\u20090.450), while aPTT agreement was insufficient (\u03ba\u2009=\u20090.220).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The CT IN\/HI ratio offers a reliable point-of-care alternative to standard UFH monitoring, in the case it is readily available. It provides better alignment with Anti-Xa activity than aPTT and may improve anticoagulation management in critically ill patients, especially when Anti-Xa testing is delayed or unavailable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      DRKS-ID DRKS00028689 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/drks.de\/search\/de\" ext-link-type=\"uri\">https:\/\/drks.de\/search\/de<\/jats:ext-link>\n                      ), PI: Lars Heubner, retrospectively registered 30.03.2022.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-026-03781-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:33:49Z","timestamp":1774348429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro\u00ae IN\/HI-Test, aPTT and Anti-Xa activity"],"prefix":"10.1186","volume":"26","author":[{"given":"Martin","family":"Mirus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Tiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Markus","family":"Spieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Heubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"4","key":"3781_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/cc4975","volume":"10","author":"M Levi","year":"2006","unstructured":"Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10(4):222.","journal-title":"Crit Care"},{"issue":"s1","key":"3781_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/anae.12908","volume":"70","author":"A Retter","year":"2015","unstructured":"Retter A, Barrett NA. The management of abnormal haemostasis in the ICU. Anaesthesia. 2015;70(s1):121-e141.","journal-title":"Anaesthesia"},{"issue":"7","key":"3781_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1097\/01.CCM.0000171207.95319.B2","volume":"33","author":"D Cook","year":"2005","unstructured":"Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005;33(7):1565\u201371.","journal-title":"Crit Care Med"},{"issue":"2, Supplement","key":"3781_CR4","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, Supplement):e24S-e43S.","journal-title":"Chest"},{"issue":"2","key":"3781_CR5","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.25011\/cim.v30i2.985","volume":"30","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med. 2007;30(2):E93-102.","journal-title":"Clin Invest Med"},{"issue":"8","key":"3781_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biomedicines9080864","volume":"8","author":"P Cauchie","year":"2021","unstructured":"Cauchie P, Piagnerelli M. What do we know about thromboprophylaxis and Its monitoring in critically ill patients? Biomedicines. 2021;8(8):864.","journal-title":"Biomedicines"},{"issue":"17","key":"3781_CR7","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.3390\/jcm11175147","volume":"11","author":"S Rajsic","year":"2022","unstructured":"Rajsic S, Breitkopf R, Jadzic D, Popovic Krneta M, Tauber H, Treml B. Anticoagulation strategies during extracorporeal membrane oxygenation: a narrative review. J Clin Med. 2022;11(17):5147.","journal-title":"J Clin Med"},{"key":"3781_CR8","doi-asserted-by":"crossref","unstructured":"P\u00f6tzsch B, Madlener K: Antikoagulation von kritisch kranken Patienten. In: H\u00e4mostaseologie. Edited by P\u00f6tzsch B, Madlener K. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010: 631\u2013635.","DOI":"10.1007\/978-3-642-01544-1_43"},{"issue":"3","key":"3781_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0950-3536(05)80017-4","volume":"3","author":"B Boneu","year":"1990","unstructured":"Boneu B, Caranobe C, Sie P. 3 pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol. 1990;3(3):531\u201344.","journal-title":"Baillieres Clin Haematol"},{"issue":"6","key":"3781_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","volume":"32","author":"JW Vandiver","year":"2012","unstructured":"Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546\u201358.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"3781_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jcp.49.1.10","volume":"49","author":"S Kitchen","year":"1996","unstructured":"Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996;49(1):10.","journal-title":"J Clin Pathol"},{"issue":"2","key":"3781_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","volume":"119","author":"P Brill-Edwards","year":"1993","unstructured":"Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119(2):104\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3781_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12185-014-1702-z","volume":"101","author":"M Mitsuguro","year":"2015","unstructured":"Mitsuguro M, Okamoto A, Shironouchi Y, Sano M, Miyata S, Neki R, et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol. 2015;101(2):119\u201325.","journal-title":"Int J Hematol"},{"issue":"6","key":"3781_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/medicina59061169","volume":"59","author":"RC Santoro","year":"2023","unstructured":"Santoro RC, Molinari AC, Leotta M, Martini T. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk! Medicina. 2023;59(6):1169.","journal-title":"Medicina"},{"issue":"3","key":"3781_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/20009666.2018.1466599","volume":"8","author":"J Durrani","year":"2018","unstructured":"Durrani J, Malik F, Ali N, Jafri SIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8(3):145\u20138.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"3","key":"3781_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11239-019-01879-w","volume":"48","author":"M Bachler","year":"2019","unstructured":"Bachler M, Niederwanger C, Hell T, H\u00f6fer J, Gerstmeyr D, Schenk B, et al. Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients. J Thromb Thrombolysis. 2019;48(3):466\u201374.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"3781_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0038-1677018","volume":"45","author":"EJ Favaloro","year":"2019","unstructured":"Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost. 2019;45(1):22\u201335.","journal-title":"Semin Thromb Hemost"},{"key":"3781_CR18","doi-asserted-by":"publisher","first-page":"107602962110669","DOI":"10.1177\/10760296211066945","volume":"27","author":"S Guy","year":"2021","unstructured":"Guy S, Kitchen S, Makris M, M. Maclean R, Saccullo G, Vanveen JJ. Caution in using the activated partial thromboplastin time to monitor argatroban in COVID-19 and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Clin Appl Thromb Hemost. 2021;27:10760296211066944.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"3781_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1160\/TH06-05-0290","volume":"96","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96(11):547\u201352.","journal-title":"Thromb Haemost"},{"key":"3781_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","volume":"157","author":"DRJ Arachchillage","year":"2017","unstructured":"Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin? Thromb Res. 2017;157:157\u201361.","journal-title":"Thromb Res"},{"issue":"1","key":"3781_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11239-012-0692-z","volume":"34","author":"R Thota","year":"2012","unstructured":"Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. J Thromb Thrombolysis. 2012;34(1):132\u20134.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3781_CR22","first-page":"305","volume":"72","author":"S van Roessel","year":"2014","unstructured":"van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014;72(6):305\u201310.","journal-title":"Neth J Med"},{"issue":"7\u20138","key":"3781_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1345\/aph.1Q161","volume":"45","author":"DJ Guervil","year":"2011","unstructured":"Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7\u20138):861\u20138.","journal-title":"Ann Pharmacother"},{"key":"3781_CR24","first-page":"5579936","volume":"2021","author":"TP Nguyen","year":"2021","unstructured":"Nguyen TP, Phan XT, Huynh DQ, Viet Truong HT, Le Hai YN, Nguyen TM, et al. Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA? Crit Care Res Pract. 2021;2021:5579936.","journal-title":"Crit Care Res Pract"},{"issue":"4","key":"3781_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1309\/AJCPS6OW6DYNOGNH","volume":"139","author":"CM Takemoto","year":"2013","unstructured":"Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, et al. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol. 2013;139(4):450\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"3781_CR26","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1055\/a-2359-0987","volume":"8","author":"I Gouin-Thibault","year":"2024","unstructured":"Gouin-Thibault I, Mansour A, Hardy M, Gu\u00e9ret P, de Maistre E, Siguret V, et al. Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points. TH Open. 2024;8(3):e297\u2013307.","journal-title":"TH Open"},{"issue":"2","key":"3781_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"J Helms","year":"2023","unstructured":"Helms J, Frere C, Thiele T, Tanaka KA, Neal MD, Steiner ME, et al. Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the scientific and standardization committees on perioperative and critical care haemostasis and thrombosis of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2023;21(2):373\u201396.","journal-title":"J Thromb Haemost"},{"key":"3781_CR28","doi-asserted-by":"crossref","unstructured":"Heubner L, Mirus M, Vicent O, G\u00fcldner A, Tiebel O, Beyer-Westendorf J, Fries D, Spieth PM: Point of care coagulation management in anesthesiology and critical care. Minerva Anestesiol 2022.","DOI":"10.23736\/S0375-9393.22.16380-7"},{"issue":"1","key":"3781_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF01618085","volume":"8","author":"DL Reich","year":"1992","unstructured":"Reich DL, Zahl K, Perucho MH, Thys DM. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monit. 1992;8(1):33\u20136.","journal-title":"J Clin Monit"},{"issue":"11","key":"3781_CR30","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1053\/j.jvca.2024.07.048","volume":"38","author":"S Rajsic","year":"2024","unstructured":"Rajsic S, Schwaiger D, Schausberger L, Breitkopf R, Treml B, Jadzic D, et al. Anticoagulation monitoring using activated clotting time in patients receiving extracorporeal membrane oxygenation: a meta-analysis of correlation coefficients. J Cardiothorac Vasc Anesth. 2024;38(11):2651\u201360.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"2","key":"3781_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/14017438409102391","volume":"18","author":"S Ottesen","year":"1984","unstructured":"Ottesen S, Stormorken H, Hatteland K. The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. Scand J Thorac Cardiovasc Surg. 1984;18(2):123\u20138.","journal-title":"Scand J Thorac Cardiovasc Surg"},{"key":"3781_CR32","doi-asserted-by":"publisher","first-page":"107602962097549","DOI":"10.1177\/1076029620975494","volume":"26","author":"JE Wehner","year":"2020","unstructured":"Wehner JE, Boehne M, David S, Brand K, Tiede A, Bikker R. Activated clotting time (ACT) for monitoring of low-dose heparin: performance characteristics in healthy adults and critically ill patients. Clin Appl Thromb Hemost. 2020;26:1076029620975494.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"3781_CR33","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1055\/s-0039-1696658","volume":"3","author":"JD Dias","year":"2019","unstructured":"Dias JD, Lopez-Espina CG, Panigada M, Dalton HJ, Hartmann J, Achneck HE. Cartridge-based thromboelastography can be used to monitor and quantify the activity of unfractionated and low-molecular-weight heparins. TH Open. 2019;3(3):e295\u2013305.","journal-title":"TH Open"},{"issue":"1","key":"3781_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12959-021-00267-w","volume":"19","author":"P Groene","year":"2021","unstructured":"Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S, et al. Viscoelastometry for detecting oral anticoagulants. Thromb J. 2021;19(1):18.","journal-title":"Thromb J"},{"issue":"9596","key":"3781_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"1","key":"3781_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","volume":"41","author":"MA Smythe","year":"2016","unstructured":"Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):165\u201386.","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"3781_CR37","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/jcm11051338","volume":"11","author":"B Lardinois","year":"2022","unstructured":"Lardinois B, Hardy M, Michaux I, Horlait G, Rotens T, Jacqmin H, et al. Monitoring of unfractionated heparin therapy in the intensive care unit using a point-of-care aPTT: a comparative, longitudinal observational study with laboratory-based aPTT and anti-Xa activity measurement. J Clin Med. 2022;11(5):1338.","journal-title":"J Clin Med"},{"issue":"1","key":"3781_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bja.2024.04.016","volume":"133","author":"D Fries","year":"2024","unstructured":"Fries D, Gratz J, Asmis L, Groene P, Heubner L, Schmitt F, et al. Clinical practice, research, and collaboration with industry: impact of the discontinuation of a critical device. Br J Anaesth. 2024;133(1):235\u20136.","journal-title":"Br J Anaesth"},{"key":"3781_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.thromres.2019.01.002","volume":"175","author":"D Ratano","year":"2019","unstructured":"Ratano D, Alberio L, Delodder F, Faouzi M, Berger MM. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res. 2019;175:53\u20138.","journal-title":"Thromb Res"},{"issue":"5","key":"3781_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/jcpt.12415","volume":"41","author":"S Samuel","year":"2016","unstructured":"Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther. 2016;41(5):499\u2013502.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3781_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1076029617741363","volume":"24","author":"E Whitman-Purves","year":"2018","unstructured":"Whitman-Purves E, Coons JC, Miller T, DiNella JV, Althouse A, Schmidhofer M, et al. Performance of anti-Factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost. 2018;24(2):310\u20136.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"3781_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s42077-019-0021-2","volume":"11","author":"HV Zaki","year":"2019","unstructured":"Zaki HV, Elbeialy MAK, Soliman AM. The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit. Ain-Shams J Anesthesiol. 2019;11(1):3.","journal-title":"Ain-Shams J Anesthesiol"},{"issue":"Suppl 2","key":"3781_CR43","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1093\/ajhp\/zxac351","volume":"80","author":"T Vo","year":"2023","unstructured":"Vo T, Bello A, Ragan M, Flanagan J, Johnson D. Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation. Am J Health Syst Pharm. 2023;80(Suppl 2):S77-s83.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"3781_CR44","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1053\/j.jvca.2013.10.010","volume":"28","author":"J Ichikawa","year":"2014","unstructured":"Ichikawa J, Kodaka M, Nishiyama K, Hirasaki Y, Ozaki M, Komori M. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28(4):1003\u20137.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"3781_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/02676591241232513","volume":"40","author":"EB Yin","year":"2024","unstructured":"Yin EB, Bracey AW, Chatterjee S. Thromboelastography versus thromboelastometry for unfractionated heparin monitoring in adult patients on extracorporeal membrane oxygenation. Perfusion. 2024;40(1):235\u201342.","journal-title":"Perfusion"},{"issue":"5","key":"3781_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12630-022-02193-5","volume":"69","author":"D Katz","year":"2022","unstructured":"Katz D, Leffert L, Getrajdman C, Sison M, Shin DW, Lin H-M, et al. The relationship between INTEM\/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation. Cand J Anesthesia\/Journal canadien d\u2019anesth\u00e9sie. 2022;69(5):597\u2013604.","journal-title":"Cand J Anesthesia\/Journal canadien d'anesth\u00e9sie"},{"issue":"5","key":"3781_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00101-025-01524-7","volume":"74","author":"M Mirus","year":"2025","unstructured":"Mirus M, Sch\u00f6chl H, Groene P, Bachler M, Koscielny J, Fries D, et al. [Point of care coagulation diagnostics-Absolutely necessary or only a reasonable supplement?]. Anaesthesiologie. 2025;74(5):264\u201374. https:\/\/doi.org\/10.1007\/s00101-025-01524-7.","journal-title":"Anaesthesiologie"},{"key":"3781_CR48","doi-asserted-by":"publisher","first-page":"109809","DOI":"10.1016\/j.jclinane.2020.109809","volume":"64","author":"AS Santos","year":"2020","unstructured":"Santos AS, Oliveira AJF, Barbosa MCL, Nogueira J. Viscoelastic haemostatic assays in the perioperative period of surgical procedures: systematic review and meta-analysis. J Clin Anesth. 2020;64:109809.","journal-title":"J Clin Anesth"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-026-03781-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:45:42Z","timestamp":1781642742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12871-026-03781-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3781"],"URL":"https:\/\/doi.org\/10.1186\/s12871-026-03781-4","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was designed in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Technische Universit\u00e4t Dresden (BO-EK-374072021). The requirement for informed consent was waived by the Dresden University Ethics Committee due to the observational design and use of de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual patient data or identifying information are included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.B.-W. has received honoraria and institutional research support from Alexion\/AstraZeneca, Bayer AG, Daiichi Sankyo, Leo Pharma, Norgine, Takeda and Pfizer. O.G. has received research funding, honoraria for lectures or consultancy support from Astra Zeneca, Alexion, Alvereon, Bayer AG, Biotest, Boehringer Ingelheim, CSL Behring, Octapharma, Novo Nordisk, Nycomed, Portola, Pfizer, Sanofi, Takeda, Werfen, DFG (Germany), and BMBF (Germany). LH received honorary for advisory boards from TAKEDA and AstraZeneca as well as honorary for lectures from AstraZeneca, CSL Behring, Werfen and Octapharma. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}